Does the media prefer CGEM or NAMS?

In the previous week, Cullinan Therapeutics had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 2 mentions for NewAmsterdam Pharma. Cullinan Therapeutics' average media sentiment score of 0.18 beat NewAmsterdam Pharma's score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CGEM or VKTX?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A

Is CGEM or VKTX more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Viking Therapeutics N/A -71.31% -65.35%

Does the media prefer CGEM or VKTX?

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 4 articles in the media. Viking Therapeutics' average media sentiment score of 0.19 beat Cullinan Therapeutics' score of 0.18 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cullinan Therapeutics (CGEM) Competitors

$13.51 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$14.47 +0.96 (+7.11%)

As of 08:38 AM Eastern

Compare

CGEM vs. NAMS, CPRX, VKTX, CRNX, and KNSA

Should you buy Cullinan Therapeutics stock or one of its competitors? MarketBeat compares Cullinan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cullinan Therapeutics include NewAmsterdam Pharma (NAMS), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Cullinan Therapeutics (NASDAQ:CGEM) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cullinan Therapeutics had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 2 mentions for NewAmsterdam Pharma. Cullinan Therapeutics' average media sentiment score of 0.18 beat NewAmsterdam Pharma's score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

Cullinan Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Cullinan Therapeutics presently has a consensus target price of $30.75, indicating a potential upside of 127.61%. NewAmsterdam Pharma has a consensus target price of $48.60, indicating a potential upside of 54.19%. Given Cullinan Therapeutics' higher probable upside, equities analysts clearly believe Cullinan Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

NewAmsterdam Pharma has higher revenue and earnings than Cullinan Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
NewAmsterdam Pharma	$22.50M	163.76	-$203.82M	-$1.79	N/A

Summary

NewAmsterdam Pharma beats Cullinan Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Cullinan Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, suggesting a potential upside of 2.33%. Cullinan Therapeutics has a consensus price target of $30.75, suggesting a potential upside of 127.61%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Catalyst Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.50	$214.33M	$1.74	17.97
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Cullinan Therapeutics had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 0 mentions for Catalyst Pharmaceuticals. Cullinan Therapeutics' average media sentiment score of 0.18 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Neutral
Cullinan Therapeutics	Neutral

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Cullinan Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 4 articles in the media. Viking Therapeutics' average media sentiment score of 0.19 beat Cullinan Therapeutics' score of 0.18 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $30.75, suggesting a potential upside of 127.61%. Viking Therapeutics has a consensus target price of $93.60, suggesting a potential upside of 229.00%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Viking Therapeutics	N/A	-71.31%	-65.35%

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Summary

Cullinan Therapeutics beats Viking Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Crinetics Pharmaceuticals?

Cullinan Therapeutics (NASDAQ:CGEM) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Cullinan Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Crinetics Pharmaceuticals	$18.07M	192.10	-$465.32M	-$5.13	N/A

Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cullinan Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 4 mentions for Cullinan Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 0.33 beat Cullinan Therapeutics' score of 0.18 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cullinan Therapeutics presently has a consensus price target of $30.75, suggesting a potential upside of 127.61%. Crinetics Pharmaceuticals has a consensus price target of $76.13, suggesting a potential upside of 131.24%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Crinetics Pharmaceuticals beats Cullinan Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International presently has a consensus target price of $60.86, suggesting a potential upside of 25.69%. Cullinan Therapeutics has a consensus target price of $30.75, suggesting a potential upside of 127.61%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Cullinan Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$754.05M	4.94	$59.01M	$0.90	53.80
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Cullinan Therapeutics had 3 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 1 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.54 beat Cullinan Therapeutics' score of 0.18 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cullinan Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kiniksa Pharmaceuticals International beats Cullinan Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$830.33M	$3.33B	$6.46B	$11.98B
Dividend Yield	N/A	2.31%	2.67%	5.55%
P/E Ratio	-4.02	19.02	23.87	23.62
Price / Sales	N/A	178.84	481.26	89.75
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.95	7.97	10.33	6.66
Net Income	-$219.88M	$23.89M	$3.57B	$337.72M
7 Day Performance	-16.66%	-5.14%	-0.92%	-3.74%
1 Month Performance	-7.15%	2.54%	3.55%	0.95%
1 Year Performance	48.79%	36.80%	23.81%	25.35%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	3.0814 of 5 stars	$13.51 flat	$30.75 +127.6%	+48.8%	$830.33M	N/A	N/A	30	Analyst Downgrade Gap Up
NAMS NewAmsterdam Pharma	2.8406 of 5 stars	$31.68 -6.0%	$48.00 +51.5%	+56.5%	$3.94B	$22.50M	N/A	4
CPRX Catalyst Pharmaceuticals	3.5967 of 5 stars	$31.28 +0.1%	$32.00 +2.3%	+20.9%	$3.82B	$588.99M	17.97	80	Positive News
VKTX Viking Therapeutics	3.4016 of 5 stars	$29.70 -9.3%	$93.60 +215.2%	+2.2%	$3.80B	N/A	N/A	20	Gap Up
CRNX Crinetics Pharmaceuticals	3.2807 of 5 stars	$33.10 -6.9%	$76.13 +130.0%	-0.3%	$3.75B	$18.07M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Cullinan Therapeutics compare to Catalyst Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. NAMS, CPRX, VKTX, CRNX, and KNSA

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Do insiders and institutionals have more ownership in CGEM or NAMS?

Does the media prefer CGEM or NAMS?

Which has more volatility and risk, CGEM or NAMS?

Is CGEM or NAMS more profitable?

Do analysts prefer CGEM or NAMS?

Which has better valuation & earnings, CGEM or NAMS?

Summary

How does Cullinan Therapeutics compare to Catalyst Pharmaceuticals?

Is CPRX or CGEM more profitable?

Do analysts prefer CPRX or CGEM?

Which has stronger earnings & valuation, CPRX or CGEM?

Does the media favor CPRX or CGEM?

Do insiders & institutionals hold more shares of CPRX or CGEM?

Which has more risk and volatility, CPRX or CGEM?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Does the media prefer CGEM or VKTX?

Do insiders and institutionals have more ownership in CGEM or VKTX?

Which has more volatility & risk, CGEM or VKTX?

Do analysts prefer CGEM or VKTX?

Is CGEM or VKTX more profitable?

Which has stronger earnings & valuation, CGEM or VKTX?

Summary

How does Cullinan Therapeutics compare to Crinetics Pharmaceuticals?

Which has higher earnings & valuation, CGEM or CRNX?

Which has more risk and volatility, CGEM or CRNX?

Do insiders and institutionals hold more shares of CGEM or CRNX?

Is CGEM or CRNX more profitable?

Does the media refer more to CGEM or CRNX?

Do analysts recommend CGEM or CRNX?

Summary

How does Cullinan Therapeutics compare to Kiniksa Pharmaceuticals International?

Which has more volatility and risk, KNSA or CGEM?

Do insiders & institutionals have more ownership in KNSA or CGEM?

Do analysts recommend KNSA or CGEM?

Is KNSA or CGEM more profitable?

Which has higher valuation & earnings, KNSA or CGEM?

Does the media favor KNSA or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools